An economic evaluation of prophylactic self-injectable epinephrine to prevent fatalities in children with mild venom anaphylaxis

Annals of Allergy, Asthma and Immunology

Volumn 99, Issue 5, 2007, Pages 424-428

  Shaker, Marcus S ^a,b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Center for the Evaluative Clinical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; VENOM;

ADOLESCENT; ADULT; ALLERGY; ANAPHYLAXIS; ARTICLE; CHEMOPROPHYLAXIS; CHILD; CHILDHOOD; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; ECONOMIC EVALUATION; ENVENOMATION; FATALITY; HUMAN; LIFE TABLE; MAJOR CLINICAL STUDY; MARKET; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SELF INJECTION; SENSITIVITY ANALYSIS; SIMULATION; SOCIETY; STATISTICAL ANALYSIS; SURVIVAL;

EID: 36048935673     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60567-4     Document Type: Article

References (22)

1. Abrishami MA, Boyd GK, Settipane GA. Prevalence of bee sting allergy in 2,010 girl scouts. Acta Allergol. 1971;26: 117-120.
2. Settipane GA, Boyd GK. Prevalence of bee sting allergy in 4,992 boy scouts. Acta Allergol. 1970;25:286-291.
3. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med. 2004;351:668-674.
4. Moffitt JE, Golden DB, Reisman RE, et al. Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol. 2004;114:869-886.
5. Sicherer SH, Simons FE. Self-injectable epinephrine for first aid management of anaphylaxis. Pediatrics. 2007;119:638-646.
6. Valentine MD, Schuberth KC, Kagey-Sobotka A, et al. The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med. 1990;323:1601-1603.
7. Confino-Cohen R, Melamed S, Goldberg A. Debilitating beliefs, emotional distress and quality of life in patients given immunotherapy for insect sting allergy. Clin Exp Allergy. 1999; 29:1626-1631.
8. Oude Elberink JN, De Monchy JG, Van Der Heide S, Guyatt GH, Dubois AE. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol. 2002;110:174-182.
9. Hunink MG. Decision Making in Health and Medicine: Integrating Evidence and Values. Cambridge, England: University Press; 2004.
10. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002;22: 417-430.
11. National Center for Health Statistics. Life tables. Available at: http://www.cdc.gov/nchs/products/pubs/pubd/lftbls/life/1966.htm. Accessed March 6, 2006.
12. Drugstore.com. EpiPen-(single Syringe) Syringe. Available at: http://www.drugstore.com/qxn49502050001_333181_sespider/epipen/epipen.htm. Accessed March 3, 2007.
13. Yocum MW, Butterfield JH, Klein JS, Volcheck GW, Schroeder DR, Silverstein MD. Epidemiology of anaphylaxis in Olmsted County: a population-based study. J Allergy Clin Immunol. 1999;104:452-456.
14. US Census Bureau. American FactFinder. Available at: http://www. factfinder.census.gov. Accessed March 2, 2007.
15. Centers for Disease Control and Prevention. CDC Wonder. Available at: http://wonder.cdc.gov. Accessed March 7, 2007.
16. Bureau of Labor Statistics Web site. Available at: http://www.bls.gov/. Accessed March 10, 2006.
17. Reisman RE. Natural history of insect sting allergy: relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions. J Allergy Clin Immunol. 1992;90:335-339.
18. WebMD. Allergies to insect stings: topic overview.. Available at: http://www.webmd.com/allergies/tc/Allergies-to-Insect-Stings-Topic-Overview. Accessed March 2, 2007.
19. O'Connor AM, Stacey D, Rovner D, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2001;(3):CD001431.
20. Vander Leek TK, Liu AH, Stefanski K, Blacker B, Bock SA. The natural history of peanut allergy in young children and its association with serum peanut-specific IgE. J Pediatr. 2000; 137:749-755.
21. US Food and Drug Administration. Omalizumab (marketed as Xolair) information. Available at: http://www.fda.gov/cder/drug/infopage/omalizumab/ default.htm. Accessed March 31, 2007.
22. Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992;327:380-384.